No title
Migraine treatments that target calcitonin gene-related peptide (CGRP) are widely used, but questions remain regarding their mechanisms and sites of action. Re-examination of the effects of CGRP in the trigeminovascular system has now refined our understanding of nociceptive CGRP signalling and underscores the importance of early therapeutic intervention.
